Mediwound Ltd (MDWD) Stock AnalysisMDWDStock AnalysisMediwound Ltd

Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain. It operates in the Healthcare sector (MEDICINAL CHEMICALS AND BOTANICAL PRODUCTS industry).

Mediwound Ltd is not a good buy right now due to significant financial losses and declining revenues. The current price is $12.66, and the company reported a net loss of $7.4 million in Q2 2026, which is concerning. Additionally, the RSI is at 32.703, indicating that the stock is oversold but may not rebound soon. The forward P/E ratio is high at 34.965, suggesting that the stock is overvalued relative to its earnings potential. The main risk is the company's reliance on government contracts, which has led to a 31.27% year-to-date decline in stock price.

5 analysts cover MDWD: 5 rate it Buy, 0 Hold and 0 Sell. The average price target is 30.00.